[The hepatotoxicity of ethionamide remains a topical subject. Apropos of a case of acute hepatitis].
The authors discuss the case of a 22 year-old patient treated for lepromatous leprosy who developed acute hepatitis 2 years after beginning polychemotherapy associating thalidomide, rifampin, ethionamide and clofazimine. Besides the ethionamide, there was no hepato-toxic factor and the hepatic anomalies quickly disappeared upon termination of treatment with this product. This again draws attention to the hepato-toxicity of ethionamide.
D000328:Adult; D056486:Chemical and Drug Induced Liver Injury / Q000209:etiology*; D005000:Ethionamide / Q000009:adverse effects* / Q000627:therapeutic use; D006801:Humans; D007918:Leprosy / Q000150:complications / Q000188:drug therapy*; D008297:Male
D005000:Ethionamide
L'hépatotoxicité de l'éthionamide reste un sujet d'actualité. A propos d'une observation d'hépatite aiguë.